The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Our vision is to empower science to end cancer metastasis. Our mission is to provide a novel microfluidic platform for enabling anti-metastatic drug discovery and precision medicine. Our novel microfluidic device is the only platform that can recreate tumour microenvironment to enrich metastatic cells for research. Together with our data analytic software, our technology empowers scientists and researchers for faster drug development and data generation, and benefits cancer patients with more drugs that target metastasis. Our clinical test, using the genetic signature of metastatic cells to predict drug response, will also enable precision medicine for more effective cancer treatments.